Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

UTMDUTAH MEDICAL PRODUCTS INC

Nasdaq · CIK 0000706698
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC3841 Surgical & Medical Instruments & Apparatus
FY end1231
XBRL facts319

Identity from submissions API

NameUTAH MEDICAL PRODUCTS INC
CIK0000706698
TickersUTMD
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC3841 Surgical & Medical Instruments & Apparatus
EIN870342734
LEI—
Fiscal year end1231
State of incorporationUT UT
Phone8015215301
Website—
Investor website—
Owner org08 Industrial Applications and Services
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
7043 S 300 WEST
MIDVALE
UT
84070
UT
Mailing address
7043 S 300 WEST
MIDVALE
UT
84047
UT

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

849 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-13 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001096906-26-001742 001-12575 261552008 34 2810592 1 1
2026-11-03 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 8.01,9.01 0001096906-26-001664 001-12575 261515830 34 146901 1 1
2026-10-29 4 PRIMARY DOCUMENT 0001733614-26-000005 4859
2026-10-29 SC TO-I/A SCHEDULE TO-I/A 0001096906-26-001646 005-34115 261500250 34 12694
2026-10-22 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-26-001602 001-12575 261478623 34 342974 1 1
2026-10-05 SC TO-I/A SCHEDULE TO-I/A 0001096906-26-001502 005-34115 261439439 34 9253
2026-09-29 SC TO-I/A SCHEDULE TO-I/A 0001096906-26-001481 005-34115 261424598 34 500065 1 1
2026-09-25 SC TO-C SCHEDULE TO-C 0001096906-26-001447 005-34115 261408412 34 13125
2026-09-24 SC TO-C SCHEDULE TO-C 0001096906-26-001439 005-34115 261405363 34 18285
2026-09-24 SC TO-I SC TO-I 0001096906-26-001428 005-34115 261402033 34 831028 1 1
2026-09-17 SC TO-C FORM SC TO-C 0001096906-26-001373 005-34115 261384785 34 17204
2026-08-31 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 7.01 0001096906-26-001326 001-12575 261345141 34 149701 1 1
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001015079-26-000089 005-34115 261279409 34 10037
2026-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001037389-26-000058 005-34115 261273890 34 9375
2026-08-12 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001096906-26-001210 001-12575 261266706 34 2381103 1 1
2026-07-23 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-26-001112 001-12575 261196754 34 283474 1 1
2026-07-01 4 PRIMARY DOCUMENT 0001733614-26-000003 4777
2026-05-29 4 PRIMARY DOCUMENT 0001733614-26-000001 4503
2026-05-27 SD UTAH MEDICAL FORM SD 0001096906-26-000865 001-12575 261024945 34 13046
2026-05-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001015079-26-000060 005-34115 26980807 34 6805
2026-05-12 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001096906-26-000767 001-12575 26968209 34 2015432 1 1
2026-05-04 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 5.07 0001096906-26-000685 001-12575 26936960 34 141385 1 1
2026-04-23 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-26-000602 001-12575 26888299 34 211799 1 1
2026-04-02 DEF 14A PROXY STATEMENT 0001096906-26-000477 001-12575 26835033 34 527931
2026-03-27 10-K UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING 0001096906-26-000395 001-12575 26808676 34 5933730 1 1
2026-03-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-002547 005-34115 26805120 34 7106
2026-01-29 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-26-000161 001-12575 26577387 34 291931 1 1
2025-12-18 3 PRIMARY DOCUMENT 0001733614-25-000007 4098
2025-11-25 4 PRIMARY DOCUMENT 0001733614-25-000004 5344
2025-11-14 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001096906-25-001839 001-12575 251484458 34 2462545 1 1
2025-11-04 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 5.02,8.01,9.01 0001096906-25-001733 001-12575 251447837 34 151911 1 1
2025-10-23 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-25-001708 001-12575 251412823 34 288482 1 1
2025-09-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001041062-25-000177 005-34115 251297361 34 6708
2025-09-05 4 PRIMARY DOCUMENT 0001733614-25-000002 4432
2025-08-26 4 PRIMARY DOCUMENT 0001733614-25-000001 4707
2025-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001041062-25-000148 005-34115 251207177 34 6716
2025-08-12 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001096906-25-001281 001-12575 251206401 34 2490596 1 1
2025-07-24 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-25-001180 001-12575 251146282 34 292311 1 1
2025-07-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-003275 005-34115 251132455 34 10708
2025-07-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000354204-25-001052 005-34115 251124755 34 8604
2025-05-28 SD UTAH MEDICAL PRODUCTS, INC. FORM SD 0001096906-25-000893 001-12575 25993761 34 12981
2025-05-15 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001096906-25-000816 001-12575 25951694 34 2109530 1 1
2025-05-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001041062-25-000110 005-34115 25946996 34 6639
2025-05-05 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 5.07 0001096906-25-000679 001-12575 25913850 34 149170 1 1
2025-04-29 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-25-000625 001-12575 25885858 34 215983 1 1
2025-04-04 DEF 14A UTAH MEDICAL PRODUCTS, INC. - DEF 14A 0001096906-25-000427 001-12575 25815769 34 467860
2025-03-26 10-K UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING 0001096906-25-000308 001-12575 25774277 34 5886429 1 1
2025-02-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-25-001340 005-34115 25592347 34 11637
2025-01-28 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-25-000095 001-12575 25563733 34 297344 1 1
2025-01-08 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-000036 005-34115 25516902 34 11251
2024-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001037389-24-000117 005-34115 241453781 34 9170
2024-11-12 SC 13G/A UnitedStates_13G__UtahMedica.txt 0000932471-24-001311 005-34115 241450372 34 6427
2024-11-12 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-24-000022 001-12575 241447238 34 2276533 1 1
2024-11-12 SC 13G/A filing.txt 0000315066-24-002914 005-34115 241444990 34 8092
2024-11-12 3 PRIMARY DOCUMENT 0001733614-24-000004 4697
2024-11-08 4 PRIMARY DOCUMENT 0001733614-24-000003 5265
2024-11-05 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 5.02,8.01,9.01 0001096906-24-002072 001-12575 241427028 34 159220 1 1
2024-11-04 SC 13G/A UnitedStates_13G__UtahMedica.txt 0000932471-24-000745 005-34115 241422524 34 5501
2024-10-31 SC 13G SEC SCHEDULE 13G 0000354204-24-004750 005-34115 241413836 34 19165
2024-10-29 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-24-002035 001-12575 241405097 34 284882 1 1
2024-08-09 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-24-000018 001-12575 241192595 34 2281635 1 1
2024-07-25 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.01,9.01 0001096906-24-001590 001-12575 241141348 34 296346 1 1
2024-07-22 4 PRIMARY DOCUMENT 0001733614-24-000002 4346
2024-05-31 SD UTAH MEDICAL PRODUCT - FORM SD 0001096906-24-001277 001-12575 241008627 34 12984
2024-05-17 4 PRIMARY DOCUMENT 0001733614-24-000001 4620
2024-05-10 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-24-000015 001-12575 24933485 34 1924843 1 1
2024-05-06 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 5.07 0001096906-24-001026 001-12575 24917140 34 143785 1 1
2024-04-25 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.01,9.01 0001096906-24-000934 001-12575 24875518 34 217782 1 1
2024-04-15 DEFA14A UTAH MEDICAL PRODUCTS, INC. FORM DEFA14A 0001096906-24-000826 001-12575 24844359 34 18227
2024-04-10 DEF 14A UTAH MEDICAL FORM DEF 14A 0001096906-24-000764 001-12575 24834055 34 381332
2024-03-26 10-K UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING 0001811884-24-000009 001-12575 24782128 34 5524762 1 1
2024-02-14 SC 13G/A utmd13gadec23.txt 0001897612-24-001141 005-34115 34 6391
2024-02-13 SC 13G/A utmd-13g_20231231.txt 0001037389-24-000065 005-34115 24623415 34 13256
2024-02-09 SC 13G/A filing.txt 0000315066-24-001569 005-34115 24612685 34 8203
2024-01-30 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-24-000127 001-12575 24577568 34 276758 1 1
2024-01-29 SC 13G/A us9174881089_012924.txt 0001086364-24-005552 005-34115 24574885 34 13258
2023-12-26 4 PRIMARY DOCUMENT 0001733614-23-000005 5271
2023-11-13 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-23-000021 001-12575 231396342 34 2208008 1 1
2023-10-31 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 8.01,9.01 0001096906-23-002066 001-12575 231363230 34 153637 1 1
2023-10-26 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-23-002058 001-12575 231349944 34 287351 1 1
2023-08-11 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-23-000017 001-12575 231162378 34 2193522 1 1
2023-07-25 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-23-001449 001-12575 231108147 34 315970 1 1
2023-07-14 S-8 UTAH MEDICAL PRODUCTS, INC. - S-8 0001096906-23-001418 333-273261 231089637 33 201369
2023-06-20 4 PRIMARY DOCUMENT 0001733614-23-000004 4241
2023-06-14 144 xsl144X01/primary_doc.xml 0001959173-23-001851 001-12575 231013084 33 4466
2023-05-30 SD UTAH MEDICAL PRODUCT - FORM SD 0001096906-23-001202 001-12575 23974424 34 13054
2023-05-19 4 PRIMARY DOCUMENT 0001733614-23-000003 4515
2023-05-18 144 xsl144X01/primary_doc.xml 0001949846-23-000088 001-12575 23936629 33 3966
2023-05-08 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 5.07 0001096906-23-000990 001-12575 23897502 34 153123 1 1
2023-05-05 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-23-000013 001-12575 23892363 34 1789631 1 1
2023-04-25 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-23-000901 001-12575 23844778 34 215366 1 1
2023-04-12 DEFA14A UTAH MEDICAL PRODUCTS, INC. FORM DEF-A-14A 0001096906-23-000785 001-12575 23815390 34 119136
2023-04-04 DEF 14A PROXY STATEMENT 0001096906-23-000725 001-12575 23795859 34 580459
2023-03-28 10-K/A UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING 0001811884-23-000008 001-12575 23769882 34 5489337 1 1
2023-03-27 10-K UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING 0001811884-23-000004 001-12575 23764785 34 5518957 1 1
2023-03-17 4 PRIMARY DOCUMENT 0001733614-23-000002 4481
2023-02-14 SC 13G utmd13gdec22.txt 0001897612-23-000640 005-34115 34 9378
2023-02-13 SC 13G/A utmd-13g_20221231.txt 0001037389-23-000057 005-34115 23615838 34 13157
2023-02-09 4 PRIMARY DOCUMENT 0001733614-23-000001 4027
2023-02-09 SC 13G/A filing.txt 0000315066-23-002111 005-34115 23605141 34 8040
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-017211 005-34115 23604513 34 12837
2023-02-01 SC 13G/A us9174881089_020123.txt 0001306550-23-006483 005-34115 23577562 34 12978
2023-01-31 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-23-000240 001-12575 23572871 34 278962 1 1
2022-12-06 4 PRIMARY DOCUMENT 0001733614-22-000009 8111
2022-11-21 4 PRIMARY DOCUMENT 0001733614-22-000008 4484
2022-11-17 4 PRIMARY DOCUMENT 0001733614-22-000007 4481
2022-11-15 4 PRIMARY DOCUMENT 0001733614-22-000006 4482
2022-11-10 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-22-000015 001-12575 221375710 34 2139841 1 1
2022-11-03 4 PRIMARY DOCUMENT 0001733614-22-000005 4209
2022-11-01 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 8.01,9.01 0001096906-22-002609 001-12575 221349635 34 154173 1 1
2022-10-25 4 PRIMARY DOCUMENT 0001733614-22-000004 5137
2022-10-25 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-22-002547 001-12575 221329030 34 306652 1 1
2022-08-12 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-22-000012 001-12575 221159135 34 2137836 1 1
2022-08-10 SC 13G/A utmd13gajul22.txt 0000080255-22-002459 005-34115 34 9533
2022-07-28 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-22-001712 001-12575 221112145 34 318217 1 1
2022-06-27 4 PRIMARY DOCUMENT 0001733614-22-000003 4484
2022-06-10 SC 13G/A utmd13gamay22.txt 0000080255-22-002351 005-34115 34 9309
2022-05-31 SD UTAH MEDICAL PRODUCTS, INC. - FORM SD 0001096906-22-001309 001-12575 22983378 34 11643
2022-05-11 4 PRIMARY DOCUMENT 0001733614-22-000002 4028
2022-05-11 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-22-000008 001-12575 22912801 34 1733730 1 1
2022-05-09 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 5.07 0001096906-22-001059 001-12575 22904268 34 165863 1 1
2022-04-27 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-22-000948 001-12575 22855618 34 229936 1 1
2022-04-13 DEF 14A PROXY STATEMENT 0001096906-22-000827 001-12575 22825074 34 495196
2022-03-25 10-K UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING 0001811884-22-000004 001-12575 22771226 34 5457961 1 1
2022-02-14 SC 13G/A utmd13gadec21.txt 0000080255-22-001907 005-34115 34 9328
2022-02-11 SC 13G/A utmd-13g_20211231.txt 0001037389-22-000199 005-34115 22620393 34 13155
2022-02-10 4 PRIMARY DOCUMENT 0001733614-22-000001 4025
2022-02-10 SC 13G/A SCHEDULE 13G/A 0001104659-22-018812 005-34115 22611055 34 12832
2022-02-09 SC 13G/A filing.txt 0000315066-22-001192 005-34115 22604670 34 8583
2022-02-08 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 8.01,9.01 0001096906-22-000265 001-12575 22600478 34 189254 1 1
2022-02-02 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-22-000245 001-12575 22580706 34 366249 1 1
2022-02-01 SC 13G/A us9174881089_013122.txt 0000834237-22-003967 005-34115 22575655 34 12978
2021-12-13 4 PRIMARY DOCUMENT 0001733614-21-000011 6646
2021-11-26 4 PRIMARY DOCUMENT 0001733614-21-000010 5886
2021-11-23 4 PRIMARY DOCUMENT 0001733614-21-000009 4430
2021-11-18 4 PRIMARY DOCUMENT 0001733614-21-000008 5499
2021-11-12 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-21-000016 001-12575 211401289 34 2128320 1 1
2021-11-02 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 8.01,9.01 0001096906-21-002618 001-12575 211370057 34 193021 1 1
2021-10-28 4 PRIMARY DOCUMENT 0001733614-21-000007 7497
2021-10-28 4 PRIMARY DOCUMENT 0001733614-21-000006 11989
2021-10-26 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-21-002587 001-12575 211347890 34 383695 1 1
2021-08-30 4 PRIMARY DOCUMENT 0001733614-21-000005 5492
2021-08-27 4 PRIMARY DOCUMENT 0001733614-21-000004 4022
2021-08-06 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-21-000012 001-12575 211151532 34 2411450 1 1
2021-07-22 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001096906-21-001665 001-12575 211106798 34 332095 1 1
2021-05-26 SD UTAH MEDICAL FORM SD 0001096906-21-001296 001-12575 21965403 34 12978
2021-05-11 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-21-000008 001-12575 21910293 34 2004208 1 1
2021-05-07 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 5.07 0001096906-21-001059 001-12575 21904048 34 178168 1 1
2021-04-23 8-K UTAH MEDICAL FORM 8-K 2.02,9.01 0001096906-21-000840 001-12575 21845975 34 83507
2021-04-12 DEF 14A PROXY STATEMENT 0001096906-21-000735 001-12575 21819090 34 465317
2021-03-26 10-K UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING 0001811884-21-000004 001-12575 21775805 34 5564497 1 1
2021-03-12 4 PRIMARY DOCUMENT 0001733614-21-000003 4483
2021-03-10 4 PRIMARY DOCUMENT 0001733614-21-000002 4024
2021-03-01 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 1.02 0001096906-21-000377 001-12575 21697974 34 180451 1 1
2021-02-16 SC 13G/A utmd13gadec20.txt 0000080255-21-001001 005-34115 34 9327
2021-02-11 SC 13G/A utmd-13g_20201231.txt 0001037389-21-000313 005-34115 21618744 34 13155
2021-02-10 SC 13G SCHEDULE 13G 0001104659-21-019329 005-34115 21612248 34 13658
2021-02-09 4 PRIMARY DOCUMENT 0001733614-21-000001 4027
2021-02-08 SC 13G/A filing.txt 0000315066-21-001343 005-34115 21599872 34 8545
2021-02-01 SC 13G/A us9174881089_013121.txt 0000834237-21-005553 005-34115 21574540 34 12959
2021-01-28 8-K UTAH MEDICAL 8-K 2.02,9.01 0001096906-21-000171 001-12575 21565103 34 168911
2020-11-09 10-Q/A UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-20-000018 001-12575 201298798 34 2382023 1 1
2020-11-06 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-20-000015 001-12575 201294243 34 2375850 1 1
2020-11-03 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 8.01,9.01 0001096906-20-000150 001-12575 201284478 34 157918 1 1
2020-10-27 8-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING 2.02,9.01 0001445866-20-001623 001-12575 201264324 34 299967 1 1
2020-08-10 8-K UTAH MEDICAL 8-K 5.07 0001445866-20-001137 001-12575 201088448 34 13434
2020-08-07 10-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING 0001811884-20-000011 001-12575 201084927 34 2320661 1 1
2020-07-28 8-K UTAH MEDICAL 8-K 2.02,9.01 0001445866-20-001050 001-12575 201053006 34 102871
2020-07-14 DEF 14A PROXY STATEMENT 0001445866-20-001001 001-12575 201026533 34 458221
2020-06-09 4 PRIMARY DOCUMENT 0001733614-20-000012 4421
2020-06-05 4 PRIMARY DOCUMENT 0001733614-20-000011 6009
2020-06-05 4 PRIMARY DOCUMENT 0001733614-20-000010 4025
2020-06-04 4 PRIMARY DOCUMENT 0001733614-20-000009 4030
2020-05-29 SD UTAH MEDICAL PRODUCTS INC - FORM SD 0001445866-20-000764 001-12575 20928647 34 13258
2020-05-28 4 PRIMARY DOCUMENT 0001733614-20-000008 4024
2020-05-28 4 PRIMARY DOCUMENT 0001733614-20-000007 4485
2020-05-27 4 PRIMARY DOCUMENT 0001733614-20-000006 4023
2020-05-22 4 PRIMARY DOCUMENT 0001733614-20-000005 4027
2020-05-19 4 PRIMARY DOCUMENT 0001733614-20-000004 4029
2020-05-13 4 PRIMARY DOCUMENT 0001733614-20-000003 4482
2020-05-11 4 PRIMARY DOCUMENT 0001733614-20-000002 4483
2020-05-08 10-Q UTAH MEDICAL 10-Q 0001445866-20-000588 001-12575 20860119 34 1534726 1
2020-04-23 8-K UTAH MEDICAL 8-K 2.02 0001445866-20-000449 001-12575 20810124 34 81068
2020-03-31 10-K/A 10KA1 0001096906-20-000131 001-12575 20761329 34 423709
2020-03-24 8-K 8K 8.01,9.01 0001096906-20-000117 001-12575 20736202 34 26045
2020-03-16 10-K 10K 0001096906-20-000111 001-12575 20718200 34 5094893 1
2020-02-21 4 PRIMARY DOCUMENT 0001733614-20-000001 4028
2020-02-14 SC 13G/A utmd13gadec19.txt 0000080255-20-001008 005-34115 34 9288
2020-02-13 SC 13G/A utmd-13g_20191231.txt 0001037389-20-000285 005-34115 20609124 34 13164
2020-02-07 SC 13G/A filing.txt 0000315066-20-001225 005-34115 20585950 34 8488
2020-02-07 SC 13G us9174881089_020620.txt 0000834237-20-008012 005-34115 20584657 34 12950
2020-01-30 8-K 8-K 2.02,9.01 0001096906-20-000051 001-12575 20561213 34 201368
2019-12-13 4 PRIMARY DOCUMENT 0001733614-19-000011 6004
2019-11-29 4 PRIMARY DOCUMENT 0001733614-19-000010 4420
2019-11-19 4 PRIMARY DOCUMENT 0001733614-19-000009 4028
2019-11-13 4 PRIMARY DOCUMENT 0001733614-19-000008 4023
2019-11-12 4 PRIMARY DOCUMENT 0001733614-19-000007 4028
2019-11-07 10-Q 10Q 0001096906-19-000361 001-12575 191201013 34 2266771 1
2019-11-07 4 PRIMARY DOCUMENT 0001733614-19-000006 4421
2019-11-07 4 PRIMARY DOCUMENT 0001733614-19-000005 4208
2019-11-05 8-K 8K 8.01,9.01 0001096906-19-000353 001-12575 191192393 34 24130
2019-10-24 8-K 8K 2.02,9.01 0001096906-19-000350 001-12575 191165891 34 226512
2019-09-13 UPLOAD filename1.pdf 0000000000-19-013576 39303
2019-09-10 CORRESP filename1.htm 0001096906-19-000326 156519
2019-09-10 UPLOAD filename1.pdf 0000000000-19-013408 43926
2019-08-09 10-Q 10Q 0001096906-19-000278 001-12575 191010958 34 2205921 1
2019-07-30 8-K 8K 2.02,9.01 0001096906-19-000270 001-12575 19984315 34 210246
2019-06-07 SC 13G/A r13gautahmed.htm 0001207017-19-000038 005-34115 19885918 34 5730
2019-05-31 SD FORM SD 0001096906-19-000228 001-12575 19869295 34 17714
2019-05-09 10-Q 10Q 0001096906-19-000172 001-12575 19808037 34 1809540 1
2019-05-06 8-K 8K 5.07 0001096906-19-000161 001-12575 19798724 34 21636
2019-04-25 8-K 8K 2.02,9.01 0001096906-19-000154 001-12575 19766469 34 195209
2019-04-05 DEF 14A DEF 14A 0001096906-19-000126 001-12575 19733125 34 935600
2019-03-14 10-K 10K 0001096906-19-000100 001-12575 19681408 34 5800631 1
2019-02-28 4 PRIMARY DOCUMENT 0001733614-19-000003 5489
2019-02-22 4 PRIMARY DOCUMENT 0001733614-19-000002 4021
2019-02-15 4 PRIMARY DOCUMENT 0001733614-19-000001 6961
2019-02-14 SC 13G/A utmd13gadec18.txt 0000080255-19-002389 005-34115 34 9287
2019-02-13 SC 13G/A utmd-13g_20181231.txt 0001037389-19-000255 005-34115 19595780 34 13099
2019-02-13 SC 13G/A filing.txt 0000315066-19-001376 005-34115 19595216 34 8494
2019-02-13 8-K 8K 2.01,9.01 0001096906-19-000061 001-12575 19592859 34 1720432
2019-02-12 SC 13G r13gutahmed.htm 0001207017-19-000002 005-34115 19587866 34 5782
2019-02-11 SC 13G/A us9174881089_021119.txt 0000215457-19-007484 005-34115 19585692 34 12126
2019-02-08 SC 13G us9174881089_020719.txt 0000215457-19-006729 005-34115 19576535 34 12996
2019-01-31 8-K 8-K 2.02,9.01 0001096906-19-000047 001-12575 19555707 34 269977
2019-01-07 8-K 8K 1.01,9.01 0001096906-19-000008 001-12575 19512977 34 21977
2018-12-17 4 PRIMARY DOCUMENT 0001733614-18-000017 4484
2018-11-28 4 PRIMARY DOCUMENT 0001733614-18-000016 5492
2018-11-16 8-K 8K 4.01,9.01 0001096906-18-000651 001-12575 181189483 34 96329
2018-11-07 10-Q 10Q 0001096906-18-000623 001-12575 181165347 34 1458123 1
2018-10-30 8-K 8K 8.01,9.01 0001096906-18-000597 001-12575 181146331 34 24384
2018-10-23 8-K 8K 2.02,9.01 0001096906-18-000572 001-12575 181133977 34 274762
2018-10-18 8-K 8K 2.02,9.01 0001096906-18-000566 001-12575 181127896 34 201285
2018-08-09 10-Q 10Q 0001096906-18-000445 001-12575 181004531 34 1409627 1
2018-07-30 4 PRIMARY DOCUMENT 0001733614-18-000015 4024
2018-06-19 4 PRIMARY DOCUMENT 0001733614-18-000014 4419
2018-06-15 4 PRIMARY DOCUMENT 0001733614-18-000013 6008
2018-06-13 4 PRIMARY DOCUMENT 0001733614-18-000012 6008
2018-06-07 4 PRIMARY DOCUMENT 0001733614-18-000011 4416
2018-06-04 4 PRIMARY DOCUMENT 0001733614-18-000010 6003
2018-05-31 SD FORM SD 0001096906-18-000283 001-12575 18870496 34 15337
2018-05-22 4 PRIMARY DOCUMENT 0001733614-18-000009 4301
2018-05-15 4 PRIMARY DOCUMENT 0001733614-18-000008 4293
2018-05-10 4 PRIMARY DOCUMENT 0001733614-18-000007 6104
2018-05-09 10-Q 10Q 0001096906-18-000230 001-12575 18817595 34 1292438 1
2018-05-09 4 PRIMARY DOCUMENT 0001733614-18-000006 4141
2018-05-08 8-K 8K 5.07 0001096906-18-000224 001-12575 18813898 34 22664
2018-05-07 4 PRIMARY DOCUMENT 0001733614-18-000005 5887
2018-04-26 8-K 8K 2.02,9.01 0001096906-18-000212 001-12575 18776977 34 253887
2018-04-09 PX14A6G PX14A6G 0001140361-18-017766 001-12575 18745038 34 30257
2018-04-03 3 PRIMARY DOCUMENT 0001733614-18-000004 5714
2018-04-02 8-K 8K 5.02 0001096906-18-000173 001-12575 18727864 34 12514
2018-03-21 4 PRIMARY DOCUMENT 0001733614-18-000003 10146
2018-03-14 4 PRIMARY DOCUMENT 0001733614-18-000002 4419
2018-03-09 4 PRIMARY DOCUMENT 0001733614-18-000001 6006
2018-03-08 DEF 14A DEF14A 0001096906-18-000129 001-12575 18675746 34 897083
2018-03-06 10-K 10K 0001096906-18-000127 001-12575 18669718 34 4838597 1
2018-02-26 4 PRIMARY DOCUMENT 0001194248-18-000006 4419
2018-02-20 4 PRIMARY DOCUMENT 0001194248-18-000005 4026
2018-02-20 4 PRIMARY DOCUMENT 0001194248-18-000004 4418
2018-02-15 4 PRIMARY DOCUMENT 0001194248-18-000003 4298
2018-02-14 SC 13G/A utmd13gadec17.txt 0000080255-18-002287 005-34115 34 9286
2018-02-14 SC 13G utmd-13g_20171231.txt 0001037389-18-000064 005-34115 18606651 34 13089
2018-02-13 4 PRIMARY DOCUMENT 0001194248-18-000002 5882
2018-02-13 SC 13G/A filing.txt 0000315066-18-001619 005-34115 18600156 34 9325
2018-02-06 4 PRIMARY DOCUMENT 0001194248-18-000001 4292
2018-01-30 8-K 8K 2.02,9.01 0001096906-18-000047 001-12575 18559229 34 222810
2017-12-15 4 PRIMARY DOCUMENT 0001194248-17-000004 4550
2017-11-07 10-Q 10Q 0001096906-17-000710 001-12575 171183087 34 1261799 1
2017-10-31 8-K 8K 8.01,9.01 0001096906-17-000699 001-12575 171165047 34 17323
2017-10-24 8-K 8K 2.02,9.01 0001096906-17-000687 001-12575 171150897 34 156085
2017-08-03 10-Q 10Q 0001096906-17-000496 001-12575 171004078 34 1253400 1
2017-07-25 8-K 8K 2.02,9.01 0001096906-17-000478 001-12575 17980198 34 171167 1 1
2017-05-31 SD SD 0001096906-17-000401 001-12575 17880887 34 15370
2017-05-08 8-K FORM 8-K 5.07 0001096906-17-000309 001-12575 17823311 34 14737
2017-05-05 10-Q 10Q 0001096906-17-000302 001-12575 17819599 34 1164954 1
2017-04-25 8-K 8K 2.02,9.01 0001096906-17-000269 001-12575 17781521 34 128567
2017-04-13 4 PRIMARY DOCUMENT 0001194248-17-000003 4550
2017-03-10 DEF 14A UTAH MEDICAL PROXY 0001096906-17-000157 001-12575 17680760 34 845354
2017-03-08 10-K 10K 0001096906-17-000145 001-12575 17674593 34 4731136 1
2017-03-02 SC 13G/A utmd13ga3.txt 0001603715-17-000015 005-34115 17659241 34 10032
2017-02-14 SC 13G/A filing.txt 0000315066-17-002119 005-34115 17605586 34 9387
2017-02-10 SC 13G/A SC 13G/A 0000052388-17-000020 005-34115 17591213 34 137629
2017-02-07 SC 13G/A utmd13gadec16.txt 0000080255-17-001230 005-34115 34 9485
2017-02-06 4 PRIMARY DOCUMENT 0001194248-17-000002 6464
2017-01-31 8-K UTAH MEDICAL PRODUCTS, INC. 8-K 2.02 0001096906-17-000056 001-12575 17560426 34 135006
2017-01-03 4 PRIMARY DOCUMENT 0001194248-17-000001 6467
2016-12-12 4 PRIMARY DOCUMENT 0001194248-16-000021 6008
2016-12-08 4 PRIMARY DOCUMENT 0001194248-16-000020 6007
2016-11-30 4 PRIMARY DOCUMENT 0001194248-16-000019 7600
2016-11-22 4 PRIMARY DOCUMENT 0001194248-16-000018 5878
2016-11-17 4 PRIMARY DOCUMENT 0001194248-16-000017 5884
2016-11-16 4 PRIMARY DOCUMENT 0001194248-16-000016 4554
2016-11-04 10-Q 10Q 0001096906-16-002007 001-12575 161974864 34 1298841 1
2016-11-01 8-K FORM 8-K 8.01,9.01 0001096906-16-001979 001-12575 161963904 34 14723
2016-10-26 8-K 8K 2.02,9.01 0001096906-16-001964 001-12575 161951241 34 171465
2016-09-15 4 PRIMARY DOCUMENT 0001194248-16-000015 4420
2016-09-12 4 PRIMARY DOCUMENT 0001194248-16-000014 4298
2016-09-08 4 PRIMARY DOCUMENT 0001194248-16-000013 4300
2016-09-08 4 PRIMARY DOCUMENT 0001194248-16-000012 6007
2016-08-31 4 PRIMARY DOCUMENT 0001194248-16-000011 6010
2016-08-16 4 PRIMARY DOCUMENT 0001194248-16-000010 4414
2016-08-12 4 PRIMARY DOCUMENT 0001194248-16-000009 4486
2016-08-08 10-Q UTAH MEDICAL PRODUCTS, INC. 10Q 2016-06-29 0001096906-16-001810 001-12575 161815274 34 1274854 1
2016-07-26 8-K UTAH MEDICAL PRODUCTS, INC. 8K 2016-07-26 2.02,9.01 0001096906-16-001767 001-12575 161784085 34 150679
2016-07-26 8-K UTAH MEDICAL PRODUCTS, INC. 8K 2016-07-26 2.02,9.01 0001096906-16-001766 001-12575 161784081 34 150679
2016-07-26 8-K UTAH MEDICAL PRODUCTS, INC. 8K 2016-07-26 2.02,9.01 0001096906-16-001765 001-12575 161784078 34 150679
2016-06-01 4 PRIMARY DOCUMENT 0001194248-16-000008 4921
2016-05-31 SD FORM SD 0001096906-16-001658 001-12575 161684783 34 13441
2016-05-27 4 PRIMARY DOCUMENT 0001194248-16-000007 6153
2016-05-19 4 PRIMARY DOCUMENT 0001194248-16-000006 6467
2016-05-06 10-Q UTAH MEDICAL PRODUCTS, INC. 10Q 2016-03-31 0001096906-16-001582 001-12575 161627049 34 1190016 1
2016-05-02 8-K UTAH MEDICAL PRODUCTS, INC. 8K 2016-04-29 5.07 0001096906-16-001571 001-12575 161612088 34 16906
2016-04-26 8-K FORM 8-K 2.02,9.01 0001096906-16-001560 001-12575 161592011 34 115149 1
2016-04-01 4 PRIMARY DOCUMENT 0001194248-16-000005 4577
2016-03-10 10-K UTAH MEDICAL PRODUCTS, INC. 10K 2015-12-31 0001096906-16-001451 001-12575 161496792 34 4676980 1
2016-03-10 DEF 14A UTAH MEDICAL PROXY 0001096906-16-001449 001-12575 161496778 34 793115
2016-02-16 SC 13G/A NINE TEN CAPITAL PARTNERS LP SC 13GA NO2 12-31-2015 (UTAH MEDICAL PRODUCTS INC) 0001140361-16-053326 005-34115 161429490 34 130483
2016-02-12 SC 13G/A filing.txt 0000315066-16-005550 005-34115 161415331 34 9260
2016-02-11 SC 13G/A SCHEDULE 13G/A 0000052388-16-000133 005-34115 161411068 34 179963
2016-02-10 SC 13G/A UTMD AS OF 12/31/2015 0000080255-16-000907 005-34115 161405319 34 34179
2016-02-02 8-K UTAH MEDICAL PRODUCTS, INC. 8K 2016-02-02 2.02 0001096906-16-001349 001-12575 161380193 34 140258
2015-12-16 CORRESP filename1.htm 0001096906-15-001282 96008
2015-12-03 UPLOAD filename1.pdf 0000000000-15-056403 159140
2015-11-06 10-Q UTAH MEDICAL PRODUCTS, INC. 10Q 2015-09-30 0001096906-15-001137 001-12575 151207097 34 1443790 1
2015-11-03 8-K UTAH MEDICAL PRODUCTS, INC. 8K 2015-11-03 8.01,9.01 0001096906-15-001123 001-12575 151192987 34 19004
2015-10-29 4 PRIMARY DOCUMENT 0001194248-15-000004 4577
2015-10-22 8-K FORM 8-K 2.02,9.01 0001096906-15-001084 001-12575 151169792 34 188270
2015-08-07 10-Q UTAH MEDICAL PRODUCTS, INC.10Q 2015-06-30 0001096906-15-000860 001-12575 151038063 34 1512211 1
2015-07-23 8-K UTAH MEDICAL PRODUCTS, INC. 8K 2015-07-23 2.02,9.01 0001096906-15-000800 001-12575 151002319 34 199114
2015-06-01 SD FORM SD 0001096906-15-000614 001-12575 15902576 34 19512
2015-05-13 4 PRIMARY DOCUMENT 0001194248-15-000003 7933
2015-05-06 10-Q UTAH MEDICAL PRODUCTS, INC. 10-Q 2015-03-31 0001096906-15-000483 001-12575 15837325 34 1670932 1
2015-05-04 8-K UTAH MEDICAL PRODUCTS, INC. 8K 2015-05-01 5.07 0001096906-15-000461 001-12575 15828795 34 25873
2015-04-23 8-K UTAH MEDICAL PRODUCTS, INC. 8K 2015-04-23 2.02,9.01 0001096906-15-000421 001-12575 15788684 34 143832
2015-04-21 4 PRIMARY DOCUMENT 0001194248-15-000002 6466
2015-04-09 4 PRIMARY DOCUMENT 0001194248-15-000001 4576
2015-03-12 DEF 14A UTAH MEDICAL PRODUCTS, INC. DEF 14A 2015-03-10 0001096906-15-000242 001-12575 15695707 34 713822
2015-03-12 10-K UTAH MEDICAL PRODUCTS, INC. 10K 2014-12-31 0001096906-15-000240 001-12575 15695696 34 6639521 1
2015-02-17 SC 13G/A NINE TEN PARTNERS LP SC 13GA NO1 12-31-2014 (UTAH MEDICAL) 0001140361-15-007296 005-34115 15622267 34 147521
2015-02-10 SC 13G/A UTMD AS OF 12/31/2014 0000080255-15-000080 005-34115 15592866 34 34165
2015-02-10 SC 13G/A SCHEDULE 13G/A 0000052388-15-000036 005-34115 15591936 34 176182
2015-01-29 8-K FORM 8-K 2.02 0001096906-15-000107 001-12575 15558038 34 154819
2014-11-12 4 PRIMARY DOCUMENT 0001194248-14-000010 6006
2014-11-04 10-Q UTAH MEDICAL PRODUCTS, INC. 10Q 2014-09-30 0001096906-14-001487 001-12575 141192838 34 1751292 1
2014-11-04 8-K UTAH MEDICAL PRODUCTS, INC. 8K 2014-11-04 8.01,9.01 0001096906-14-001484 001-12575 141192749 34 20987
2014-11-04 8-K UTAH MEDICAL PRODUCTS, INC. 8K 2014-10-31 1.01 0001096906-14-001481 001-12575 141192054 34 117125
2014-10-27 4 PRIMARY DOCUMENT 0001194248-14-000009 4577
2014-10-24 8-K FORM 8-K 1.01 0001096906-14-001444 001-12575 141171625 34 26122
2014-10-23 8-K FORM 8-K 2.02 0001096906-14-001439 001-12575 141169322 34 162662
2014-10-15 S-8 FORM S-8 0001096906-14-001419 333-199337 141157569 33 145152
2014-10-10 4 PRIMARY DOCUMENT 0001194248-14-000008 6468
2014-08-08 10-Q UTAH MEDICAL PRODUCTS, INC. 10Q 2014-06-30 0001096906-14-001021 001-12575 141027020 34 1751282 1
2014-07-24 8-K FORM 8-K 2.02 0001096906-14-000941 001-12575 14990523 34 165193
2014-07-10 SC 13G NTCM 13G 0001603715-14-000008 005-34115 14969440 34 6654
2014-07-10 SC 13G/A BCM 13G-A9 0001340807-14-000031 005-34115 14969301 34 6457
2014-06-10 SC 13G/A UTMD 13GA-8 0001340807-14-000023 005-34115 14901592 34 6319
2014-06-02 SD UTAH MEDICAL PRODUCTS INC SD 12-31-2013 0001140361-14-024066 001-12575 14884080 34 16583
2014-05-07 4 PRIMARY DOCUMENT 0001194248-14-000007 5254
2014-05-07 10-Q UTAH MEDICAL PRODUCTS, INC. 10-Q 2014-03-31 0001096906-14-000606 001-12575 14820471 34 1627099 1
2014-05-06 4 PRIMARY DOCUMENT 0001194248-14-000006 7931
2014-05-06 8-K UTAH MEDICAL PRODUCTS, INC. FORM 8-K 5.07 0001096906-14-000593 001-12575 14816349 34 20554
2014-04-24 8-K UTAH MEDICAL PRODUCTS, INC. FORM 8-K 2.02 0001096906-14-000529 001-12575 14781045 34 126031
2014-04-01 4 PRIMARY DOCUMENT 0001194248-14-000005 6156
2014-03-14 4 PRIMARY DOCUMENT 0001194248-14-000004 5883
2014-03-12 DEF 14A UTAH MEDICAL PRODUCTS, INC. DEF 14A 0001096906-14-000295 001-12575 14687354 34 788275
2014-03-12 10-K UTAH MEDICAL PRODUCTS, INC. 10-K 2013-12-31 0001096906-14-000293 001-12575 14687343 34 6779393 1
2014-03-10 4 PRIMARY DOCUMENT 0001194248-14-000003 6006
2014-03-06 4 PRIMARY DOCUMENT 0001194248-14-000002 6007
2014-02-28 4 PRIMARY DOCUMENT 0001194248-14-000001 6007
2014-02-18 SC 13G/A UTMD 13G-A7 0001340807-14-000013 005-34115 14620387 34 6320
2014-02-14 SC 13G/A filing.txt 0000315066-14-002604 005-34115 14610282 34 8043
2014-02-13 SC 13G/A SCHEDULE 13G/A 0000052388-14-000052 005-34115 14605254 34 142685
2014-02-13 8-K FORM 8-K 5.03 0001096906-14-000174 001-12575 14603341 34 276817
2014-02-10 SC 13G/A UTMD AS OF 12/31/2013 0000080255-14-000171 005-34115 14588063 34 38083
2014-01-30 8-K UTAH MEDICAL PRODUCTS, INC FORM 8-K 2.02 0001096906-14-000092 001-12575 14559500 34 146513
2013-12-11 CORRESP filename1.htm 0001096906-13-001854 33293
2013-12-10 4 PRIMARY DOCUMENT 0001194248-13-000018 6008
2013-12-05 4 PRIMARY DOCUMENT 0001194248-13-000017 6010
2013-11-27 UPLOAD filename1.pdf 0000000000-13-065087 156014
2013-11-26 4 PRIMARY DOCUMENT 0001194248-13-000016 8315
2013-11-22 4 PRIMARY DOCUMENT 0001194248-13-000015 6006
2013-11-15 4 PRIMARY DOCUMENT 0001194248-13-000014 6007
2013-11-12 CORRESP filename1.htm 0001096906-13-001677 62301
2013-11-06 10-Q UTAH MEDICAL PRODUCTS, INC. 10Q 2013-09-30 0001096906-13-001652 001-12575 131196594 34 1697899 1
2013-10-31 4 PRIMARY DOCUMENT 0001194248-13-000013 6007
2013-10-29 8-K FORM 8-K 8.01 0001096906-13-001600 001-12575 131175554 34 19366
2013-10-24 8-K FORM 8-K 2.02 0001096906-13-001597 001-12575 131167693 34 152323
2013-10-11 UPLOAD filename1.pdf 0000000000-13-056388 162222
2013-10-01 CORRESP filename1.htm 0001096906-13-001542 26747
2013-09-19 UPLOAD filename1.pdf 0000000000-13-051710 158974
2013-09-13 CORRESP filename1.htm 0001096906-13-001481 40448
2013-09-12 4 PRIMARY DOCUMENT 0001194248-13-000012 7595
2013-09-03 4 PRIMARY DOCUMENT 0001194248-13-000011 5886
2013-08-30 UPLOAD filename1.pdf 0000000000-13-047997 162892
2013-08-26 4 PRIMARY DOCUMENT 0001194248-13-000010 6047
2013-08-15 4 PRIMARY DOCUMENT 0001194248-13-000009 4460
2013-08-12 4 PRIMARY DOCUMENT 0001194248-13-000008 6044
2013-08-08 10-Q UTAH MEDICAL PRODUCTS, INC., 10Q 2013-06-30 0001096906-13-001234 001-12575 131021060 34 2235405 1
2013-08-07 4 PRIMARY DOCUMENT 0001194248-13-000007 6047

Latest XBRL company facts

One latest value per concept from companyfacts (319 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 2.85M 2026-11-12 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
dei EntityListingParValuePerShare Entity Listing, Par Value Per Share USD/shares 0.01 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
dei EntityPublicFloat Entity Public Float USD 168.20M 2025-06-30 2025 FY 10-K 2026-03-27 0001096906-26-000395
ffd NetFeeAmt NetFeeAmt USD 0 2026-09-29 SC TO-I/A 2026-09-29 0001096906-26-001481
ffd TtlFeeAmt TtlFeeAmt USD 6,732.38 2026-09-29 SC TO-I/A 2026-09-29 0001096906-26-001481
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-09-29 SC TO-I/A 2026-09-29 0001096906-26-001481
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 6,732.38 2026-09-29 SC TO-I/A 2026-09-29 0001096906-26-001481
ffd TtlTxValtn TtlTxValtn USD 48.75M 2026-09-29 SC TO-I/A 2026-09-29 0001096906-26-001481
us-gaap AcceleratedShareRepurchasesFinalPricePaidPerShare Accelerated Share Repurchases, Final Price Paid Per Share USD/shares 64.7 2024-10-01 2024-11-11 2024 Q3 10-Q 2024-11-12 0001811884-24-000022
us-gaap AccountsAndOtherReceivablesNetCurrent Accounts and Other Receivables, Net, Current USD 3.52M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 1.68M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap AccountsReceivableGrossCurrent Accounts Receivable, before Allowance for Credit Loss, Current USD 4.04M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 3.96M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap AccruedIncomeTaxesCurrent Accrued Income Taxes, Current USD 327,000 2023-12-31 2023 FY 10-K 2024-03-26 0001811884-24-000009
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 3.06M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 25.34M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap AccumulatedOtherComprehensiveIncomeLossBeforeTax Accumulated Other Comprehensive Income (Loss), before Tax (Deprecated 2009-01-31) USD -3.37M 2013-03-31 2013 Q1 10-Q 2013-05-08 0001096906-13-000677
us-gaap AccumulatedOtherComprehensiveIncomeLossBeforeTax1 AOCI Including Portion Attributable to Noncontrolling Interest, before Tax USD -10.02M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 0 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap AdjustmentForAmortization Amortization USD 5.00M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-12 0001811884-21-000016
us-gaap AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD 50,000 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities USD -85,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 373,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap AllowanceForDoubtfulAccountsReceivableCurrent Accounts Receivable, Allowance for Credit Loss, Current USD 515,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap AmortizationOfIntangibleAssets Amortization of Intangible Assets USD 514,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap Assets Assets USD 128.50M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap AssetsCurrent Assets, Current USD 100.63M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap AvailableForSaleSecurities Available-for-sale Securities USD -183,000 2012-09-30 2012 Q3 10-Q 2012-11-09 0001096906-12-002669
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax USD 0 2018-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax USD 0 2018-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
us-gaap AvailableForSaleSecuritiesAmortizedCost Available-for-sale Securities, Amortized Cost Basis USD 0 2018-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
us-gaap AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2 Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) USD 9,000 2014-12-31 2014 FY 10-K 2015-03-12 0001096906-15-000240
us-gaap AvailableForSaleSecuritiesEquitySecurities Available-for-sale Securities, Equity Securities USD 0 2018-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
us-gaap AvailableForSaleSecuritiesGrossRealizedGains Available-for-sale Securities, Gross Realized Gains USD 32,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
us-gaap AvailableForSaleSecuritiesGrossRealizedLosses Available-for-sale Securities, Gross Realized Losses USD 12,000 2012-01-01 2012-12-31 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap AvailableforsaleSecuritiesGrossUnrealizedGain Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) USD 16,000 2014-12-31 2014 FY 10-K 2015-03-12 0001096906-15-000240
us-gaap AvailableForSaleSecuritiesGrossUnrealizedGainLoss Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2013-01-31) USD 2,000 2014-12-31 2014 FY 10-K 2015-03-12 0001096906-15-000240
us-gaap AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) USD -6,000 2015-07-01 2015-09-30 2015 Q3 10-Q 2015-11-06 0001096906-15-001137
us-gaap AvailableForSaleSecuritiesGrossUnrealizedLosses1 Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) USD -316,000 2011-12-31 2012 FY 10-K 2013-03-07 0001096906-13-000305
us-gaap AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss Available-for-sale Securities, Income Tax Expense on Change in Unrealized Holding Gain (Loss) (Deprecated 2018-01-31) USD 3,000 2015-07-01 2015-09-30 2015 Q3 10-Q 2015-11-06 0001096906-15-001137
us-gaap BuildingsAndImprovementsGross Buildings and Improvements, Gross USD 14.38M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap BusinessAcquisitionPurchasePriceAllocationAssetsAcquired Business Acquisition, Purchase Price Allocation, Assets Acquired (Deprecated 2013-01-31) USD 51.92M 2011-03-18 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net (Deprecated 2013-01-31) USD 41.08M 2011-03-18 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap BusinessAcquisitionPurchasePriceAllocationCurrentAssetsInventory Business Acquisition, Purchase Price Allocation, Current Assets, Inventory (Deprecated 2013-01-31) USD 1.32M 2011-03-18 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap BusinessAcquisitionPurchasePriceAllocationCurrentAssetsPrepaidExpenseAndOtherAssets Business Acquisition, Purchase Price Allocation, Current Assets, Prepaid Expense and Other Assets (Deprecated 2013-01-31) USD 773,000 2011-03-18 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap BusinessAcquisitionPurchasePriceAllocationCurrentAssetsReceivables Business Acquisition, Purchase Price Allocation, Current Assets, Receivables (Deprecated 2013-01-31) USD 2.18M 2011-03-18 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap BusinessAcquisitionPurchasePriceAllocationCurrentLiabilitiesAccountsPayable Business Acquisition, Purchase Price Allocation, Current Liabilities, Accounts Payable (Deprecated 2013-01-31) USD 1.11M 2011-03-18 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap BusinessAcquisitionPurchasePriceAllocationCurrentLiabilitiesAccruedLiabilities Business Acquisition, Purchase Price Allocation, Current Liabilities, Accrued Liabilities (Deprecated 2013-01-31) USD 644,000 2011-03-18 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap BusinessAcquisitionPurchasePriceAllocationDeferredTaxLiabilitiesNoncurrent Business Acquisition, Purchase Price Allocation, Deferred Tax Liabilities, Noncurrent (Deprecated 2013-01-31) USD 9.08M 2011-03-18 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap BusinessAcquisitionPurchasePriceAllocationGoodwillAmount Business Acquisition, Purchase Price Allocation, Goodwill Amount (Deprecated 2013-01-31) USD 8.25M 2011-03-18 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap BusinessAcquisitionPurchasePriceAllocationLiabilitiesAssumed Business Acquisition, Purchase Price Allocation, Liabilities Assumed (Deprecated 2013-01-31) USD 10.84M 2011-03-18 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap BusinessAcquisitionPurchasePriceAllocationPropertyPlantAndEquipment Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment (Deprecated 2013-01-31) USD 606,000 2011-03-18 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap BusinessAcquisitionsProFormaNetIncomeLoss Business Acquisition, Pro Forma Net Income (Loss) USD 10.17M 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-07 0001096906-13-000305
us-gaap BusinessAcquisitionsProFormaRevenue Business Acquisition, Pro Forma Revenue USD 41.55M 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-07 0001096906-13-000305
us-gaap BusinessCombinationAcquiredReceivablesGrossContractualAmount Business Combination, Acquired Receivables, Gross Contractual Amount USD 681,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap BusinessCombinationAcquisitionRelatedCosts Business Combination, Acquisition Related Costs USD 173 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets USD 6.16M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation USD 26,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents USD 506,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other USD 15,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets USD 21,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable USD 305,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other USD 26,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory USD 857,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities USD 1.26M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net USD 4.89M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment USD 381,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 85.20M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD -3.17M 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-08 0001445866-20-000588
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 85.20M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -554,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap CommitmentsAndContingencies Commitments and Contingencies USD 0 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 50.00M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 3.17M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 3.17M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap CommonStockValue Common Stock, Value, Issued USD 32,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD 7.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap ConstructionInProgressGross Construction in Progress, Gross USD 110,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ContractualObligation Contractual Obligation USD 4.34M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap CostOfGoodsAndServicesSold Cost of Goods and Services Sold USD 10.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap CostOfGoodsSold Cost of Goods Sold (Deprecated 2018-01-31) USD 7.95M 2018-01-01 2018-06-30 2018 Q2 10-Q 2018-08-09 0001096906-18-000445
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 2.65M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD 319,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 3.44M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 474,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD -44,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap DeferredForeignIncomeTaxExpenseBenefit Deferred Foreign Income Tax Expense (Benefit) USD -559,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap DeferredIncomeTaxesAndOtherAssetsCurrent Deferred Income Taxes and Other Assets, Current USD 393,000 2016-12-31 2016 FY 10-K 2017-03-08 0001096906-17-000145
us-gaap DeferredIncomeTaxesAndOtherAssetsNoncurrent Deferred Income Taxes and Other Assets, Noncurrent USD 777,000 2011-09-30 2011 Q3 10-Q 2011-11-07 0001096906-11-002591
us-gaap DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent Deferred Income Taxes and Other Tax Liabilities, Noncurrent USD 944,000 2013-12-31 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD -148,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap DeferredIncomeTaxLiabilitiesNet Deferred Income Tax Liabilities, Net USD 303,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD -10,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap DeferredTaxAssetsInventory Deferred Tax Assets, Inventory USD 254,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD -3.56M 2017-12-31 2017 FY 10-K 2018-03-06 0001096906-18-000127
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 0 2019-12-31 2019 FY 10-K 2020-03-16 0001096906-20-000111
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 43,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts USD 76,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap DeferredTaxExpenseFromStockOptionsExercised Deferred Tax Expense from Stock Options Exercised USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-12 0001096906-26-001210
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 488,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap DeferredTaxLiabilitiesGoodwillAndIntangibleAssets Deferred Tax Liabilities, Goodwill and Intangible Assets USD 8.05M 2012-09-30 2012 Q3 10-Q 2012-11-09 0001096906-12-002669
us-gaap DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets Deferred Tax Liabilities, Intangible Assets USD 0 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap DeferredTaxLiabilitiesNoncurrent Deferred Tax Liabilities, Net, Noncurrent USD 521,000 2019-12-31 2019 FY 10-K 2020-03-16 0001096906-20-000111
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 211,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap Depreciation Depreciation USD 638,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 820,000 2012-01-01 2012-03-31 2012 Q1 10-Q 2012-05-09 0001096906-12-001242
us-gaap DividendsCommonStockCash Dividends, Common Stock, Cash USD 2.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap DueFromOtherRelatedPartiesCurrent Due from Other Related Parties, Current USD 15,000 2012-12-31 2012 FY 10-K 2013-03-07 0001096906-13-000305
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares 2.54 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares 2.54 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0.239 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure 0.003 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.004 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.036 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017TransitionTaxOnAccumulatedForeignEarningsAmount Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Transition Tax on Accumulated Foreign Earnings, Amount USD 0 2022-01-01 2022-12-31 2022 FY 10-K/A 2023-03-28 0001811884-23-000008
us-gaap EffectOfExchangeRateOnCashAndCashEquivalents Effect of Exchange Rate on Cash and Cash Equivalents USD -362,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-25 0001811884-22-000004
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD -243,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 853,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 1.01M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions Share-based Payment Arrangement, Exercise of Option, Tax Benefit USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options (Deprecated 2017-01-31) USD 50,000 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-08 0001096906-17-000145
us-gaap ExcessTaxBenefitFromShareBasedCompensationOperatingActivities Excess Tax Benefit from Share-based Compensation, Operating Activities USD -39,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-25 0001811884-22-000004
us-gaap FairValueMeasuredOnRecurringBasisInvestments Fair Value, Measured on Recurring Basis, Investments (Deprecated 2011-01-31) USD 47,000 2013-03-31 2013 Q1 10-Q 2013-05-08 0001096906-13-000677
us-gaap FiniteLivedCustomerRelationshipsGross Finite-Lived Customer Relationships, Gross USD 9.61M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap FiniteLivedIntangibleAssetsAccumulatedAmortization Finite-Lived Intangible Assets, Accumulated Amortization USD 34.16M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Finite-Lived Intangible Asset, Expected Amortization, Year One USD 433,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five USD 1.98M 2016-12-31 2016 FY 10-K 2017-03-08 0001096906-17-000145
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four USD 1.98M 2016-12-31 2016 FY 10-K 2017-03-08 0001096906-17-000145
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Finite-Lived Intangible Asset, Expected Amortization, Year Five USD 9,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Finite-Lived Intangible Asset, Expected Amortization, Year Four USD 9,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Finite-Lived Intangible Asset, Expected Amortization, Year Three USD 10,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Finite-Lived Intangible Asset, Expected Amortization, Year Two USD 12,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap FiniteLivedIntangibleAssetsFutureAmortizationExpense Finite-Lived Intangible Assets, Future Amortization Expense (Deprecated 2012-01-31) USD 2.60M 2017-01-01 2017-12-31 2012 FY 10-K 2013-03-07 0001096906-13-000305
us-gaap FiniteLivedIntangibleAssetsGross Finite-Lived Intangible Assets, Gross USD 38.05M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap FiniteLivedIntangibleAssetsNet Finite-Lived Intangible Assets, Net USD 840,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap FiniteLivedNoncompeteAgreementsGross Finite-Lived Noncompete Agreements, Gross USD 134,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap FiniteLivedPatentsGross Finite-Lived Patents, Gross USD 2.22M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap FiniteLivedTrademarksGross Finite-Lived Trademarks, Gross USD 9.87M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ForeignCurrencyExchangeRateTranslation Foreign Currency Exchange Rate, Translation (Deprecated 2012-01-31) pure 1.626 2012-12-31 2012 FY 10-K 2013-03-07 0001096906-13-000305
us-gaap ForeignCurrencyExchangeRateTranslation1 Foreign Currency Exchange Rate, Translation pure 1.559 2014-12-31 2014 FY 10-K 2015-03-12 0001096906-15-000240
us-gaap GainLossOnDispositionOfAssets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property USD 0 2022-01-01 2022-12-31 2022 FY 10-K/A 2023-03-28 0001811884-23-000008
us-gaap GainLossOnInvestments Gain (Loss) on Investments USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-26 0001811884-21-000004
us-gaap GainLossOnSaleOfInvestments Gain (Loss) on Sale of Investments USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-26 0001811884-21-000004
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 7.88M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap Goodwill Goodwill USD 13.96M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap GoodwillAcquiredDuringPeriod Goodwill, Acquired During Period USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
us-gaap GoodwillForeignCurrencyTranslationGainLoss Goodwill, Foreign Currency Translation Gain (Loss) USD 472,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap GoodwillImpairmentLoss Goodwill, Impairment Loss USD 0 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap GrossProfit Gross Profit USD 14.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD 11.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD 9.87M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 2.31M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest USD 8.72M 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-06 0001811884-21-000012
us-gaap IncomeTaxesPaid Income Taxes Paid USD 2.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap IncomeTaxesReceivable Income Taxes Receivable, Current USD 0 2018-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 1.79M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap IncomeTaxExpenseBenefitContinuingOperations Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) USD 3.07M 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD 2.90M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap IncomeTaxPaidForeignAfterRefundReceived IncomeTaxPaidForeignAfterRefundReceived USD 4.30M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap IncomeTaxReconciliationDeductionsQualifiedProductionActivities Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Amount USD 6,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-25 0001811884-22-000004
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD -1,000 2024-12-31 2024 FY 10-K 2025-03-26 0001096906-25-000308
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD 2.48M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 30,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD -43,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 428,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 15,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 778,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -338,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets Increase (Decrease) in Accounts Receivable and Other Operating Assets USD 60,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 1.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap IncreaseDecreaseInDeferredIncomeTaxes Increase (Decrease) in Deferred Income Taxes USD -659,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD 0 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-10 0001096906-16-001451
us-gaap IncreaseDecreaseInInventories Increase (Decrease) in Inventories USD 2.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap IncreaseDecreaseInOperatingCapital Increase (Decrease) in Operating Capital USD 203,000 2014-01-01 2014-06-30 2014 Q2 10-Q 2014-08-08 0001096906-14-001021
us-gaap IncreaseDecreaseInOtherNoncurrentLiabilities Increase (Decrease) in Other Noncurrent Liabilities USD 0 2014-01-01 2014-09-30 2014 Q3 10-Q 2014-11-04 0001096906-14-001487
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD 0 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-10 0001096906-16-001451
us-gaap IncreaseDecreaseInOtherReceivables Increase (Decrease) in Other Receivables USD 5,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 382,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap IntangibleAssetsNetExcludingGoodwill Intangible Assets, Net (Excluding Goodwill) USD 3.88M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap InterestExpense Interest Expense USD 65,000 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-06 0001096906-18-000127
us-gaap InterestIncomeSecuritiesTaxExempt Interest Income, Securities, Operating, Tax Exempt USD 201,000 2024-12-31 2024 FY 10-K 2025-03-26 0001096906-25-000308
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap InterestReceivableAndOtherAssets Interest Receivable and Other Assets USD 53,000 2023-12-31 2023 FY 10-K 2024-03-26 0001811884-24-000009
us-gaap InventoryFinishedGoodsNetOfReserves Inventory, Finished Goods, Net of Reserves USD 2.63M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap InventoryNet Inventory, Net USD 10.57M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap InventoryRawMaterials Inventory, Raw Materials, Gross USD 5.90M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap InventoryWorkInProcess Inventory, Work in Process, Gross USD 2.03M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap InvestmentsFairValueDisclosure Investments, Fair Value Disclosure USD 0 2018-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
us-gaap Land Land USD 1.70M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 307,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 32,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 60,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 47,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 46,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 45,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 56,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 21,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap Liabilities Liabilities USD 5.22M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 128.50M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap LiabilitiesCurrent Liabilities, Current USD 4.74M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap LitigationReserve Estimated Litigation Liability USD 68,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap LitigationReserveCurrent Estimated Litigation Liability, Current USD 68,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap LongTermDebt Long-term Debt USD 0 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap LongTermDebtAndCapitalLeaseObligations Long-term Debt and Lease Obligation USD 180,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 4,052 2013-12-31 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four USD 1,000 2012-12-31 2012 FY 10-K 2013-03-07 0001096906-13-000305
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 1,013 2013-12-31 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 4,052 2013-12-31 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap LongTermNotesPayable Notes Payable, Noncurrent USD 0 2015-12-31 2015 FY 10-K 2016-03-10 0001096906-16-001451
us-gaap MachineryAndEquipmentGross Machinery and Equipment, Gross USD 19.05M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD -3.76M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -4.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD 7.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap NotesPayableCurrent Notes Payable, Current USD 0 2015-12-31 2015 FY 10-K 2016-03-10 0001096906-16-001451
us-gaap OperatingExpenses Operating Expenses USD 6.87M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap OperatingIncomeLoss Operating Income (Loss) USD 8.01M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap OperatingLeaseCost Operating Lease, Cost USD 67,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 286,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 60,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 226,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 286,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 45,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 618,000 2018-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 60,000 2020-12-31 2021 Q2 10-Q 2021-08-06 0001811884-21-000012
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 45,000 2020-12-31 2021 Q2 10-Q 2021-08-06 0001811884-21-000012
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 45,000 2020-12-31 2021 Q2 10-Q 2021-08-06 0001811884-21-000012
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 45,000 2020-12-31 2021 Q2 10-Q 2021-08-06 0001811884-21-000012
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 45,000 2020-12-31 2021 Q2 10-Q 2021-08-06 0001811884-21-000012
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 254,000 2020-12-31 2021 Q2 10-Q 2021-08-06 0001811884-21-000012
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 59,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.041 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 1.68M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap OtherAssetsCurrent Other Assets, Current USD 898,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax (Deprecated 2012-01-31) USD -2.52M 2013-01-01 2013-03-31 2013 Q1 10-Q 2013-05-08 0001096906-13-000677
us-gaap OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent USD 819,000 2012-01-01 2012-09-30 2012 Q3 10-Q 2012-11-09 0001096906-12-002669
us-gaap OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax (Deprecated 2012-01-31) USD 0 2013-01-01 2013-03-31 2013 Q1 10-Q 2013-05-08 0001096906-13-000677
us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax USD -602,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001096906-20-000111
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001096906-20-000111
us-gaap OtherFiniteLivedIntangibleAssetsGross Other Finite-Lived Intangible Assets, Gross USD 21.00M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap OtherInterestAndDividendIncome Other Interest and Dividend Income USD 2.81M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 0 2024-12-31 2024 FY 10-K 2025-03-26 0001096906-25-000308
us-gaap OtherLongTermDebtNoncurrent Other Long-term Debt, Noncurrent USD 241,000 2025-09-30 2025 Q3 10-Q 2025-11-14 0001096906-25-001839
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 1.86M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap OtherOperatingIncomeExpenseNet Other Operating Income (Expense), Net USD -32,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-06 0001096906-18-000127
us-gaap OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities Other than Temporary Impairment Losses, Investments, Available-for-sale Securities USD 290,000 2012-01-01 2012-12-31 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 905,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap PaymentsOfDividends Payments of Dividends USD 2.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap PaymentsToAcquireBusinessesNetOfCashAcquired Payments to Acquire Businesses, Net of Cash Acquired USD 4.04M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap PaymentsToAcquireIntangibleAssets Payments to Acquire Intangible Assets USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap PaymentsToAcquireInvestments Payments to Acquire Investments USD 0 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-07 0001096906-19-000361
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 500,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.01 2020-09-30 2020 Q3 10-Q/A 2020-11-09 0001811884-20-000018
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 5.00M 2020-09-30 2020 Q3 10-Q/A 2020-11-09 0001811884-20-000018
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2020-09-30 2020 Q3 10-Q/A 2020-11-09 0001811884-20-000018
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2020-09-30 2020 Q3 10-Q/A 2020-11-09 0001811884-20-000018
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2020-09-30 2020 Q3 10-Q/A 2020-11-09 0001811884-20-000018
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 418,000 2015-12-31 2015 FY 10-K 2016-03-10 0001096906-16-001451
us-gaap ProceedsAndExcessTaxBenefitFromSharebasedCompensation Proceeds and Excess Tax Benefit from Share-based Compensation USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001096906-20-000111
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 129,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap ProceedsFromNotesPayable Proceeds from Notes Payable USD 0 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap ProceedsFromSaleOfAvailableForSaleSecurities Proceeds from Sale of Available-for-sale Securities USD 74,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-14 0001096906-19-000100
us-gaap ProceedsFromSaleOfBuildings Proceeds from Sale of Buildings USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-26 0001811884-21-000004
us-gaap ProceedsFromSaleOfLongtermInvestments Proceeds from Sale of Long-term Investments USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-26 0001811884-21-000004
us-gaap ProceedsFromSaleOfProductiveAssets Proceeds from Sale of Productive Assets USD 27,000 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-10 0001811884-24-000015
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ProductWarrantyAccrual Standard and Extended Product Warranty Accrual USD 0 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD 8.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 35.25M 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 10.02M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap ProvisionForDoubtfulAccounts Accounts Receivable, Credit Loss Expense (Reversal) USD -414,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap RepaymentsOfNotesPayable Repayments of Notes Payable USD 4.78M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-06 0001096906-18-000127
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 450,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD 133.26M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 25.87M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2021-04-01 2021-06-30 2021 Q2 10-Q 2021-08-06 0001811884-21-000012
us-gaap RoyaltyIncomeNonoperating Royalty Income, Nonoperating USD 20,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap SalesRevenueNet Revenue, Net (Deprecated 2018-01-31) USD 21.85M 2018-01-01 2018-06-30 2018 Q2 10-Q 2018-08-09 0001096906-18-000445
us-gaap SellingAndMarketingExpense Selling and Marketing Expense USD 2.05M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap SellingGeneralAndAdministrativeExpense Selling, General and Administrative Expense USD 6.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 269,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments USD 0.325 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) pure 3.8 2012-01-01 2012-12-31 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.311 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.038 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised shares 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized shares 275,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 65,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (Deprecated 2011-01-31) shares 55,287 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-12 0001096906-14-000293
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 700 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures shares 24,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 16.74 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 0 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 121,000 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price USD/shares 70.95 2023-12-31 2023 FY 10-K 2024-03-26 0001811884-24-000009
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit USD/shares 49.18 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-26 0001811884-24-000009
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable shares 48,485 2023-12-31 2023 FY 10-K 2024-03-26 0001811884-24-000009
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding shares 84,301 2023-12-31 2023 FY 10-K 2024-03-26 0001811884-24-000009
us-gaap SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price USD/shares 74.56 2023-12-31 2023 FY 10-K 2024-03-26 0001811884-24-000009
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit USD/shares 82.6 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-26 0001811884-24-000009
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 123.28M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD 123.28M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-27 0001096906-26-000395
us-gaap StockOptionPlanExpense Stock or Unit Option Plan Expense USD 269,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap StockRepurchasedAndRetiredDuringPeriodShares Stock Repurchased and Retired During Period, Shares shares 48,905 2024-10-01 2024-11-11 2024 Q3 10-Q 2024-11-12 0001811884-24-000022
us-gaap StockRepurchasedAndRetiredDuringPeriodValue Stock Repurchased and Retired During Period, Value USD -905,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap TaxBenefitFromStockOptionsExercised Tax Benefit from Stock Options Exercised (Deprecated 2012-01-31) USD 175,000 2013-01-01 2013-03-31 2013 Q1 10-Q 2013-05-08 0001096906-13-000677
us-gaap TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-25 0001811884-22-000004
us-gaap TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent USD 698,000 2023-12-31 2023 FY 10-K 2024-03-26 0001811884-24-000009
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 4,000 2020-01-01 2020-12-31 2022 FY 10-K/A 2023-03-28 0001811884-23-000008
us-gaap WeightedAverageNumberDilutedSharesOutstandingAdjustment Weighted Average Number Diluted Shares Outstanding Adjustment shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 3.18M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 3.18M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001096906-26-001742

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →